ICR welcomes FDA approval of first-in-class breast cancer drug 17 Nov 2023 The ICR strongly welcomes the news that a new targeted drug, capivasertib, has been approved by the US FDA for treating the most common type of advanced breast cancer. The drug was discovered by pharmaceutical company AstraZeneca following a programme of drug discovery research at the ICR in collaboration with Astex Pharmaceuticals. Find out more Show/Hide
New targeted drug shows benefit against breast cancer in first phase III trial 08 Dec 2022 A new type of targeted medicine has shown ‘remarkable’ benefits for patients with advanced breast cancer in a major phase III clinical trial. Find out more Show/Hide